^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HLX11 (pertuzumab biosimilar)

    i
    Other names: HLX11
    Associations

    News

    Trials
    Company:
    Fosun Pharma, Organon
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer. (PubMed, J Transl Med)
    These results suggested that the application of non-competing antibodies HLX22 and HLX02 targeting HER2 subdomain IV together may be of substantial benefit to gastric cancer patients who currently respond suboptimal to trastuzumab therapy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor) • mTOR (Mechanistic target of rapamycin kinase) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • PI3K (Phosphoinositide 3-kinases)
    |
    Hercessi (trastuzumab-strf) • HLX22 • HLX11 (pertuzumab biosimilar)
    7ms
    A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=900, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER negative • PGR negative
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • HLX11 (pertuzumab biosimilar)
    over2years
    A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=900, Recruiting, Shanghai Henlius Biotech | Trial primary completion date: Dec 2023 --> Nov 2024
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER negative • PGR negative
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • HLX11 (pertuzumab biosimilar)
    over2years
    A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=900, Recruiting, Shanghai Henlius Biotech
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER negative • PGR negative
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • HLX11 (pertuzumab biosimilar)